The company, founded in 2002, is committed to discovering and developing drug candidates targeting various brain disorders, neurodegenerative diseases, genetic disorders, and cancer. Their clinical-stage products include DR Cysteamine, currently in Phase IIb for nephropathic cystinosis and Phase IIa for non-alcoholic steatohepatitis. They are also developing Convivia for ALDH2 deficiency in Phase IIa trials, DR Cysteamine in Phase II for Huntington's Disease, and Tezampanel and NGX 426 in Phase II for migraine, acute pain, and chronic pain. HepTide for Hepatocellular Carcinoma and Hepatitis C, WntTide for breast cancer, and NeuroTrans for neurodegenerative diseases are among their preclinical products. The company collaborates with the University of California, San Diego for clinical studies on DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and patients with cystinosis. They received a significant $85.50MPost-IPO Equity investment on 02 April 2015. Raptor Pharmaceuticals Corp. continues to be a driving force in the biopharma, biotechnology, and health and wellness industries, with headquarters in Novato, California.
Raptor Pharmaceuticals
Embarking on a journey to better health through innovative biotechnology solutions for brain, genetic, and cancer disorders.
General Information
Get notified when Raptor Pharmaceuticals moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Raptor Pharmaceuticals
Get real-time alerts for funding, hiring, news, and 40+ signal types.
See how it worksDiscover More
About Raptor Pharmaceuticals
Taxonomy: pharmaceuticals, drug development, clinical trials, neurodegenerative diseases, genetic disorders, cancer research, clinical-stage products, preclinical development, University of California San Diego, clinical studies, brain disorders, Huntington's Disease, migraine treatment
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Post-IPO Equity | •••••• | - | 02 Apr 2015 | |
| Post-IPO Debt | •••••• | 1 |
|
01 Jul 2014 |
| Post-IPO Debt | •••••• | - | 20 Dec 2012 | |
| Post-IPO Equity | •••••• | 5 |
|
09 Aug 2010 |
| Post-IPO Equity | •••••• | - | 14 Sep 2009 |
Raptor Pharmaceuticals Alternatives & Competitors
Combines existing drugs with it's proprietary for enhanced drug delivery across the blood-brain barr...
Pioneering Therapeutics to Combat Inflammatory Diseases, Pioneering Better Health
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development o...
FAQ About Raptor Pharmaceuticals
Don't just browse. Track.
Signal Tracker monitors Raptor Pharmaceuticals and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.